CRISPR Gene-Editing Trial in US 2026 | High Cholesterol Treatment, Clinical Results, Patients & Key Facts

CRISPR Gene-Editing Trial in US

CRISPR Gene-Editing Trial in US 2026 centers on CTX310, an experimental cholesterol therapy that cut LDL cholesterol by 52.5% and triglycerides by 47.8% at the highest dose after 12 months in a 15-patient trial led by Cleveland Clinic. That Phase 1a trial ran in Australia, New Zealand and the UK, not the US, and no CRISPR cholesterol treatment has FDA approval.

CRISPR Gene-Editing Trial in US 2026 – Introduction

CRISPR Gene-Editing Trial in US headlines in 2026 need one correction up front. The 15-patient CTX310 trial that lowered cholesterol with a single infusion took place at 6 sites in Australia, New Zealand and the UK. Cleveland Clinic led it, and the New England Journal of Medicine published the 12-month results on August 28, 2026. CTX310 is experimental. The FDA has not approved it, and a Phase 1b study with US sites is now underway.

The US side of the story is just as real. The FDA approved Casgevy, a CRISPR-based therapy, for children aged 2 and older on July 1, 2026. Intellia’s lonvo-z now sits under priority FDA review with a decision due March 10, 2027. This report separates experimental trials from approved medicines, sticks to FDA, Cleveland Clinic, NEJM and company filings, and reflects data available on November 19, 2026.

Interesting Facts About CRISPR Gene-Editing Trial in US 2026

Fact 2026 Data
CTX310 Phase 1a participants 15
LDL cholesterol reduction, highest dose, 12 months 52.5%
Triglyceride reduction, highest dose 47.8%
ANGPTL3 protein reduction, highest dose 78.6%
Phase 1a trial locations 6 sites in Australia, New Zealand and the UK
Planned long-term safety follow-up 15 years
FDA-approved CRISPR therapy Casgevy, ages 2 and older (July 1, 2026)
Casgevy revenue, third quarter 2026 $99.2 million
Lonvo-z FDA decision date March 10, 2027
Gene-editing trials tracked worldwide 306 (July 31, 2026)

Source: Cleveland Clinic and New England Journal of Medicine, August 28, 2026; U.S. Food and Drug Administration (FDA); Vertex Pharmaceuticals third quarter 2026 results; Intellia Therapeutics SEC filing, September 8, 2026; CRISPR Medicine News.

CTX310 switches off the ANGPTL3 gene in the liver with a single infusion. The protein fell 78.6% at the highest dose, which pulled LDL cholesterol down 52.5% and triglycerides down 47.8% at 12 months. Those are averages from a handful of patients at the top dose, so they describe early promise, not proven benefit.

The other rows show where approval stands. Casgevy is the only approved CRISPR therapy, and it treats blood disorders. No cholesterol editor has reached an FDA decision. The CRISPR Gene-Editing Trial in US question therefore has two answers: experimental cholesterol trials are early, while approved gene editing already treats sickle cell disease.

CRISPR Gene-Editing Statistics in the US 2026

Measure Figure
FDA-approved CRISPR therapies 1 (Casgevy)
FDA-approved CRISPR cholesterol therapies 0
Pending FDA decision on an in vivo CRISPR therapy 1 (lonvo-z, March 10, 2027)
FDA-recommended follow-up for gene-editing therapies Up to 15 years
US adults with total cholesterol of 240 mg/dL or higher 11.3% (nearly 25 million)

Source: U.S. Food and Drug Administration (FDA); Intellia Therapeutics SEC filing, September 8, 2026; Centers for Disease Control and Prevention (CDC), NHANES August 2021-August 2023; Eli Lilly and Company, May 25, 2026.

The US has 1 approved CRISPR therapy and 1 more under review. Casgevy uses an ex vivo method: doctors edit a patient’s cells in a lab and return them. Lonvo-z would be the first approved in vivo therapy, edited inside the body. CTX310 and Lilly’s VERVE-102 are also in vivo, but both remain in early trials.

Cholesterol shows why the field targets it. About 11.3% of US adults have total cholesterol of 240 mg/dL or higher, nearly 25 million people. Many take daily pills and struggle to keep it up. A one-time edit could change that, but only larger trials can show whether it prevents heart attacks.

Number of Gene-Editing Clinical Trials Worldwide in 2026

Measure Figure Date
Gene-editing trials tracked (CRISPR Medicine News) 306 July 31, 2026
Gene-editing trials tracked earlier About 250 February 2025
Ongoing CRISPR trials 136 December 2025
Ongoing in vivo CRISPR trials 36 December 2025
Leading countries by trial count United States, China July 2026

Source: CRISPR Medicine News, CMN Intelligence Global Clinical Trials Database, Q2 2026 report; Drug Delivery, January 2026 survey of CRISPR trials.

The tracked count grew from about 250 in February 2025 to 306 by July 31, 2026, a gain of 56 trials, or 22%. The United States and China lead by trial count. A separate survey found 136 ongoing CRISPR trials in December 2025, and 36 of them delivered the editor directly into the body.

Counts differ by source because each database defines a gene-editing trial differently. Treat 306 as a tracker’s total, not an official registry figure. The shift toward in vivo work matters most. It points researchers toward one-time infusions, like CTX310, in place of cell-by-cell lab editing.

FDA-Approved Gene-Editing Treatments in the US 2026

Measure Figure
Original US approval December 2023 (sickle cell), January 2024 (beta thalassemia)
Age expansion From 12 and older to 2 and older on July 1, 2026
FDA review time for expansion 53 days
Additional US children now eligible About 5,500
Efficacy-evaluable children with no severe pain crises for 12 months 8 of 8

Source: U.S. Food and Drug Administration (FDA), Casgevy approval announcement, July 1, 2026; Vertex Pharmaceuticals news release, July 1, 2026.

The FDA expanded Casgevy to children aged 2 and older 53 days after filing, using its national priority voucher program. The decision rested on a small trial: 11 children aged 5 to 11 with sickle cell disease and 15 with transfusion-dependent beta thalassemia. All 8 sickle cell patients with evaluable data stayed free of severe pain crises for 12 months.

Vertex says about 5,500 more US children can now receive the therapy. The treatment requires full myeloablative conditioning, a high-intensity step before the edited cells return. Extrapolation from the older trial data supported the ages 2 to 4, so those children were not studied directly.

CRISPR Trials for Cholesterol and Heart Disease in the US 2026

Measure CTX310 VERVE-102
Target gene ANGPTL3 PCSK9
Participants 15 35
Highest-dose LDL reduction 52.5% (12 months) 62% (up to 18 months)
Target protein reduction 78.6% (ANGPTL3) 88% (PCSK9)
Next step Phase 1b with US sites Phase 2 by end of 2026

Source: Cleveland Clinic and New England Journal of Medicine, August 2026; Eli Lilly and Company, Heart-2 trial results, May 25, 2026; New England Journal of Medicine, May 2026.

Two one-time editors lead the cholesterol field. CTX310 targets ANGPTL3 and reached 52.5% LDL lowering plus 47.8% triglyceride lowering. VERVE-102, a base editor now owned by Lilly, targets PCSK9 and reached up to 62% LDL lowering in 35 patients with familial hypercholesterolemia or early heart disease. FDA granted VERVE-102 Fast Track status.

Neither trial measured heart attacks or strokes. Both were built to test safety first, and both used small groups at escalating doses. VERVE-102 results spanned 9% to 62% across six dose groups, so the top figure comes from the highest dose only. Larger Phase 2 studies must show the effect holds in more varied patients.

CTX310 Trial Participants, Sites and Doses in 2026

Measure Figure
Participants 15 adults (13 male, 2 female)
Age range reported 31 to 68 years
Study period June 2024 to August 2025
Sites 6, in Australia, New Zealand and the UK
Dose range 0.1 to 0.8 mg/kg, 5 dose levels

Source: Cleveland Clinic news release, November 8, 2025; American Heart Association Scientific Sessions 2025; New England Journal of Medicine, 2025-2026.

Cleveland Clinic led a trial that enrolled 15 adults between June 2024 and August 2025. Each person received one infusion at one of 5 dose levels from 0.1 to 0.8 mg/kg. Participants had inherited or mixed lipid disorders that medicines had not controlled. Only 2 of the 15 were women, which limits what the results say about female patients.

Sites sat in Australia, New Zealand and the UK, so the results may not carry to US patients. The company’s Phase 1b study uses a fixed dose matching 0.8 mg/kg and adds US sites. Treating a CRISPR Gene-Editing Trial in US result as proven for Americans would overstate the evidence.

Sickle Cell Gene-Editing Patients Treated and Sales in 2026

Measure Figure
Casgevy revenue, Q3 2026 $99.2 million (30% above Q2)
Casgevy revenue, Q3 2025 $16.9 million
Nine-month revenue, 2026 vs 2025 $218.5 million vs $61.5 million
People with a first cell collection, through Sept 30, 2025 About 165
People infused, through Sept 30, 2025 39

Source: Vertex Pharmaceuticals, third quarter 2026 and third quarter 2025 financial results, November 2, 2026 and November 3, 2025.

Casgevy sales climbed from $16.9 million to $99.2 million between the third quarters of 2025 and 2026, nearly 6 times higher. Nine-month revenue rose 3.6 times to $218.5 million. Vertex expects Casgevy and its pain drug to bring in $500 million or more combined this year.

Patient counts are older. Through September 30, 2025, about 165 people had a first cell collection and 39 had received infusions. Vertex has not published a newer infusion total in its third quarter release, though it says multiple children have started treatment since the July approval. The therapy requires weeks of cell collection before infusion.

Clinical Trial Safety and Success Rates for Gene Editing in 2026

Trial Result
CTX310 (15 patients) Related adverse events in 7 (47%); infusion reactions 3 (20%); no dose-limiting toxicity
VERVE-102 (35 patients) No treatment-related serious events; liver enzyme rises in 3
Lonvo-z HAELO (80 patients) 87% fewer attacks; 62% attack-free vs 11% on placebo
Casgevy label 100% of trial patients had severe low blood counts

Source: Cleveland Clinic and CRISPR Therapeutics presentation, August 28, 2026; Eli Lilly and Company, May 25, 2026; Intellia Therapeutics, April 27, 2026; U.S. Food and Drug Administration (FDA).

Safety looks manageable in early data. In CTX310, 7 of 15 patients had an adverse event judged related to treatment, and 3 had infusion reactions that resolved. No dose-limiting toxicity occurred through 12 months. Two earlier serious events were judged unrelated. VERVE-102 reported no treatment-related serious events across 35 patients.

Efficacy is clearest in the largest trial. Lonvo-z cut hereditary angioedema attacks 87% in 80 patients, and 62% stayed attack-free against 11% on placebo. Casgevy’s label carries a different warning: all treated patients had severe low blood counts after conditioning. Edits cannot be undone, so every program commits to long follow-up.

Gene-Editing Funding and the Future of CRISPR Medicine in 2026

Milestone Timing
Lonvo-z FDA decision March 10, 2027
VERVE-102 Phase 2 start By end of 2026
CTX310 Phase 1b severe hypertriglyceridemia update Second half of 2026
CTX310 long-term safety follow-up 15 years
Gene-editing market projection $30.5 billion by 2033

Source: Intellia Therapeutics SEC filing, September 8, 2026; Eli Lilly and Company, May 25, 2026; CRISPR Therapeutics, August 28, 2026; Persistence Market Research projection, July 7, 2026.

The next year brings real tests. The FDA decides on lonvo-z on March 10, 2027. Lilly plans to start a VERVE-102 Phase 2 study by the end of 2026, and CRISPR Therapeutics expects Phase 1b data in severe hypertriglyceridemia in the second half of 2026. The CTX310 trial was funded by CRISPR Therapeutics, so industry money drives these programs.

The $30.5 billion market projection comes from a market research firm, not a federal agency. Treat it as an estimate. A verified federal funding total for gene-editing trials was not available for this report. Trials of thousands of patients, followed for many years, must show that one-time edits prevent heart attacks before any cholesterol editor becomes standard care.

Frequently Asked Questions About CRISPR Gene-Editing Trial in US 2026

What Is the CRISPR Gene-Editing Trial for High Cholesterol in 2026?

It tests CTX310, a one-time infusion that switches off the ANGPTL3 gene in the liver. In 15 patients, the highest dose cut LDL cholesterol 52.5% and triglycerides 47.8% at 12 months. Cleveland Clinic led the trial.

Was the CTX310 Gene-Editing Trial Conducted in the US in 2026?

No. The Phase 1a trial ran at 6 sites in Australia, New Zealand and the UK. The follow-on Phase 1b study adds sites in the United States and elsewhere.

Is CTX310 FDA Approved in 2026?

No. CTX310 is experimental. No CRISPR cholesterol therapy has FDA approval in 2026.

How Many Patients Were in the CTX310 Trial in 2026?

15 adults took part, 13 men and 2 women. Each received a single infusion at one of 5 dose levels and has been followed for at least 12 months.

Is CRISPR Cholesterol Treatment Safe in 2026?

Early data are encouraging but limited. No dose-limiting toxicity occurred through 12 months, and 7 of 15 patients had treatment-related adverse events, mostly infusion reactions. Fifteen patients cannot show rare risks.

How Long Will CTX310 Patients Be Monitored in 2026?

For 15 years, as the FDA recommends for gene-editing therapies. Participants also had at least 12 months of follow-up inside the trial itself.

What CRISPR Treatments Are FDA Approved in 2026?

Casgevy for sickle cell disease and transfusion-dependent beta thalassemia, now for ages 2 and older. Lonvo-z for hereditary angioedema awaits a March 10, 2027 decision.

Can Children Get CRISPR Gene Editing for Sickle Cell in 2026?

Yes. The FDA approved Casgevy on July 1, 2026 for children aged 2 and older. About 5,500 more US children became eligible.

How Many Gene-Editing Clinical Trials Are There in 2026?

CRISPR Medicine News tracked 306 trials as of July 31, 2026. Another survey counted 136 ongoing CRISPR trials in December 2025, with 36 delivered inside the body.

Will CRISPR Replace Statins in 2026?

Not yet. Most trial participants stayed on their usual medicines, and the edit lowered cholesterol further. Nobody has tested whether it can replace daily treatment.

Is the CTX310 Gene Edit Permanent in 2026?

It is designed to be permanent. Results hold for 12 months, but nobody knows the effect over decades. That is why monitoring runs 15 years.

When Will New CRISPR Cholesterol Trial Results Arrive in 2026?

CRISPR Therapeutics expects Phase 1b data in severe hypertriglyceridemia in the second half of 2026. Lilly plans a VERVE-102 Phase 2 start by the end of 2026.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.